Search Articles — Sudonull

https://sudonull.com/web-application-vulnerabilities-xss-sqli-enumeration

Breakdown of top-3 vulnerabilities in web: user enumeration, XSS, SQL injections. Fix methods for developers: prepared statements, encoding. In-depth pentest guide.

https://sudonull.com/gamma-flip-in-algorithmic-trading-analysis-and-application

How Gamma Exposure Determines Market Regimes and Volatility. Calculation of Net GEX, Interpretation of Gamma Flip, Practical Recommendations for Traders.

https://sudonull.com/types-of-artificial-intelligence-classification-and-application

Learn about four key approaches to creating AI outside of neural networks. Comparison of advantages and limitations for developers. Read more!

https://sudonull.com/c4-model-for-it-infrastructure-practical-application

How to adapt the C4 model for designing fault-tolerant clusters. Critical errors at the HLD stage and methods to prevent them. Guide for engineers.

https://sudonull.com/labeled-break-in-c-15-practical-application

We analyze when labeled break and continue in C# 15 are really needed, and when it's better to use refactoring. Examples for developers.

https://ymaho.com/pediatric-dovato-ema-approves-application-for-hiv-therapy

EMA validated the application for pediatric Dovato (dolutegravir/lamivudine) for children from 2 years old. Learn how two-drug therapy is changing HIV treatment standards.

https://ymaho.com/ema-accepted-the-application-for-dovato-for-children-with-hiv

EMA validated the application for the use of Dovato in children from 3 months with HIV. Learn how this will change pediatric therapy and strengthen ViiV's position. Read the detailed analysis.

https://ymaho.com/pediatric-dovato-viiv-application-and-geopolitics-of-the-hiv-market

ViiV has submitted applications to the FDA and EMA for dispersible Dovato tablets for children. We analyze the strategy, patents, and implications. Find out who will win.

https://ymaho.com/study-of-the-ottava-robot-forte-results-and-fda-application

Scientists have completed the pivotal study of the Ottava robot (FORTE) and are preparing an FDA application. Learn about clinical data, zero conversions, and market prospects for robotic surgery.

https://ymaho.com/gene-therapy-for-deafness-otarmeni-ema-accelerated-review-2026

EMA accepted the application for gene therapy otarmeni for the treatment of hereditary deafness OTOF. Market analysis, forecasts, price and implications for the industry. Read.

https://ymaho.com/spacex-ipo-filing-for-75-billion-and-valuation-of-1-75-trillion

SpaceX filed an application for the largest IPO in history on Nasdaq up to $75 billion. Valuation $1.75 trillion, listing in June 2026. Analysis of the record, consequences and hidden details. Read more.

https://ymaho.com/intellia-crispr-therapy-fda-filing-for-lonvo-z-for-hae

Intellia has filed the world's first application for an in vivo CRISPR therapy, lonvo-z, for hereditary angioedema (HAE). 87% reduction in attacks, 62% attack-free. Risk, market, and forecast analysis. Read.

https://lrivo.com/linlithgow-rose-spfl-play-off-exclusion-due-to-licence

Linlithgow Rose miss SPFL play-offs after SFA bronze licence application declined. Brora Rangers face Edinburgh City in final. Learn why.

https://ymaho.com/ai-for-early-diagnosis-of-gallbladder-cancer-accuracy-92-97

PGIMER AI model analyzes ultrasound and detects gallbladder cancer at an early stage. Free application for hospitals. Data from The Lancet. Learn more.

https://ymaho.com/ipo-of-uznif-uzbekistan-s-entry-onto-the-london-stock-exchange-for-1-95-billion

Dual IPO of Uzbekistan's National Fund for $1.95 billion in Tashkent and London. GDR price — $25. Submit your application by May 12 and learn the placement details.